Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial

Christina U. Lorentz, Erik I. Tucker, Norah G. Verbout, Joseph J. Shatzel, Sven R. Olson, Brandon D. Markway, Michael Wallisch, Martina Ralle, Monica T. Hinds, Owen J. T. McCarty, David Gailani, Jeffrey I. Weitz, András Gruber

Blood (2021) 138 (22): 2173–2184.

https://doi.org/10.1182/blood.2021011725

Published: 2021

Includes: Supplemental data

Journal Articles

Management of Edoxaban Therapy in Patients Undergoing Major Surgery: A Sub-Analysis of the Prospective, Observational, Multinational Emit-AF/VTE Study

Christian von Heymann, Martin Unverdorben, Paolo Colonna, Amparo Santamaria Ortiz, Manish Saxena, Thomas Vanassche, Jeffrey I. Weitz, Robert Wilkins, Cathy Chen

Blood (2021) 138 (Supplement 1): 3024.

https://doi.org/10.1182/blood-2021-150875

Published: 2021

Journal Articles

Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial

Christina U Lorentz, PhD, Norah G Verbout, PhD, Joseph J Shatzel, MD, Michael Wallisch, PhD, Brandon D Markway, PhD, Monica T Hinds, PhD, Owen J T McCarty, PhD, David Gailani, MD, Jeffrey I. Weitz, MDFRCPC, Erik I Tucker, PhD, András Gruber, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-139948

Published: 2020

Journal Articles

Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis

Frits I. Mulder, Floris T. M. Bosch, Annie M. Young, Andrea Marshall, Robert D. McBane, II, Tyler J. Zemla, Marc Carrier, Pieter Willem Kamphuisen, Patrick M. M. Bossuyt, Harry R. Büller, Jeffrey I. Weitz, Saskia Middeldorp, Nick van Es

Blood (2020) 136 (12): 1433–1441.

https://doi.org/10.1182/blood.2020005819

Published: 2020

Includes: Supplemental data

Journal Articles

COVID-19 coagulopathy, thrombosis, and bleeding

Noel C. Chan, Jeffrey I. Weitz

Blood (2020) 136 (4): 381–383.

https://doi.org/10.1182/blood.2020007335

Published: 2020

Journal Articles

Novel antithrombotic strategies for treatment of venous thromboembolism

Jeffrey I. Weitz, Noel C. Chan

Blood (2020) 135 (5): 351–359.

https://doi.org/10.1182/blood.2019000919

Published: 2020

Journal Articles

Association of Bleeding Severity with Mortality with Extended Thromboprophylaxis in the Medically Ill in the Mariner Trial

Alex C. Spyropoulos, MD, Walter Ageno, Gregory W. Albers, MD, C. Gregory Elliott, MD, Jonathan L. Halperin, MD, William R. Hiatt, Gregory Maynard, MD, P. Gabriel Steg, MD, Jeffrey I. Weitz, MD, Theodore E. Spiro, MD, Wentao Lu, PhD, Chiara Sugarmann, BSN, MSHS, Concetta Lipardi, MD PhD, Gary E. Raskob, PhD, Elliot S. Barnathan, MD

Blood (2019) 134 (Supplement_1): 3669.

https://doi.org/10.1182/blood-2019-122621

Published: 2019

Journal Articles

Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial

Alex C. Spyropoulos, MD, Gary E. Raskob, PhD, Alexander T Cohen, MBBS, MSc, MD, Walter Ageno, Jeffrey I. Weitz, MD, Theodore E. Spiro, MD, Wentao Lu, PhD, Concetta Lipardi, MD PhD, Elliot S. Barnathan, MD

Blood (2019) 134 (Supplement_1): 2441.

https://doi.org/10.1182/blood-2019-122930

Published: 2019

Journal Articles

Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study

Gary E. Raskob, PhD, Alex C. Spyropoulos, MD, Alexander T Cohen, MBBS, MSc, MD, Jeffrey I. Weitz, MD, Walter Ageno, Yoriko De Sanctis, MS, Wentao Lu, PhD, Jianfeng Xu, PhD, John Albanese, BS, MBA, Chiara Sugarmann, BSN, MSHS, Concetta Lipardi, MD PhD, Theodore E. Spiro, MD, Elliot S. Barnathan, MD

Blood (2019) 134 (Supplement_1): 163.

https://doi.org/10.1182/blood-2019-122934

Published: 2019

Journal Articles

MAA868 locks factor XIa in a zymogen-like state

Jeffrey I. Weitz, Noel C. Chan

Blood (2019) 133 (13): 1393–1394.

https://doi.org/10.1182/blood-2019-02-900480

Published: 2019

Journal Articles

Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism

Blood (2018) 132 (Supplement 1): 2527.

https://doi.org/10.1182/blood-2018-99-113589

Published: 2018

Journal Articles

Medically Ill Patients with Moderate Renal Insufficiency Have More Thrombotic and Bleeding Events Than Those with Normal Renal Function: Insights from the Magellan and Mariner Trials of Extended Thrombprophylaxis

Jeffrey I. Weitz, MD, Gary E. Raskob, PhD, Alex C. Spyropoulos, MD, Alexander T Cohen, MD, Theodore E. Spiro, MD, Yoriko De Sanctis, MS, Jianfeng Xu, PhD, Eunyoung Suh, PhD, Wentao Lu, PhD, Concetta Lipardi, MDPhD, Elliot S. Barnathan, MD

Blood (2018) 132 (Supplement 1): 1236.

https://doi.org/10.1182/blood-2018-99-111911

Published: 2018

Journal Articles

Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism

Clive Kearon, Sameer Parpia, Frederick A. Spencer, Trevor Baglin, Scott M. Stevens, Kenneth A. Bauer, Steven R. Lentz, Craig M. Kessler, James D. Douketis, Stephan Moll, Scott Kaatz, Sam Schulman, Jean M. Connors, Jeffrey S. Ginsberg, Luciana Spadafora, Vinai Bhagirath, Patricia C. Liaw, Jeffrey I. Weitz, Jim A. Julian

Blood (2018) 131 (19): 2151–2160.

https://doi.org/10.1182/blood-2017-09-805689

Published: 2018

Includes: Supplemental data

Journal Articles

A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study

Gary E. Raskob, PhD, Nick Van Es, MD, Peter Verhamme, MD PhD, Marc Carrier, MD, Marcello Di Nisio, MD, David A. Garcia, MD, Michael A. Grosso, MD, Ajay K. Kakkar, MBBS, Michael J. Kovacs, MD, Michele F. Mercuri, MD PhD FAHA, Guy Meyer, MD, Annelise Segers, MD, Minggao Shi, PhD, Tzu-Fei Wang, MD, Erik Yeo, MD FACP, FRCPC, George Zhang, PhD, Jeffrey I. Zwicker, MD, Jeffrey I. Weitz, MD, Harry R. Büller, MD PhD

Blood (2017) 130 (Supplement 1): LBA-6.

https://doi.org/10.1182/blood.V130.Suppl_1.LBA-6.LBA-6

Published: 2017

Journal Articles

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in the Prevention of Venous Thromboembolism after Elective Hip or Knee Replacement Surgery

Scott D. Berkowitz, MD, Keith A A Fox, MBBS, Stephan Schmidt, Jeffrey I Weitz, MD FRCPC, FACP, Dirk Garmann, Dagmar Kubitza, Wolfgang Mueck, Gary Peters, MD, Isabel Reinecke, Alexander Solms, Theodore E Spiro, MD, Xiaoyu Yan, PhD MSc, Liping Zhang, Stefan Willmann

Blood (2017) 130 (Supplement 1): 3718.

https://doi.org/10.1182/blood.V130.Suppl_1.3718.3718

Published: 2017

Journal Articles

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients Treated for Venous Thromboembolism

Scott D. Berkowitz, MD, Jeffrey I Weitz, MD FRCPC, FACP, Stephan Schmidt, Keith A A Fox, MBBS, Dirk Garmann, Dagmar Kubitza, Wolfgang Mueck, Gary Peters, MD, Isabel Reinecke, Alexander Solms, Theodore E Spiro, MD, Xiaoyu Yan, PhD MSc, Liping Zhang, Stefan Willmann

Blood (2017) 130 (Supplement 1): 1104.

https://doi.org/10.1182/blood.V130.Suppl_1.1104.1104

Published: 2017

Journal Articles

The Effect of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients with Nonvalvular Atrial Fibrillation

Xiaoyu Yan, PhD MSc, Gary Peters, MD, Amarnath Sharma, Partha Nandy, Christopher Nessel, MD, Dirk Garmann, Stefan Willmann, Anne Hermanowski-Vosatka, Alexander Solms, Scott D. Berkowitz, MD, Theodore E Spiro, MD, Keith A A Fox, MBBS, Jeffrey I Weitz, MD FRCPC, FACP, Stephan Schmidt, Jonathan P Piccini, Manesh Patel, Richard C Becker, Liping Zhang

Blood (2017) 130 (Supplement 1): 1107.

https://doi.org/10.1182/blood.V130.Suppl_1.1107.1107

Published: 2017

Journal Articles

Platelet polyphosphate: the long and the short of it

Jeffrey I. Weitz, James C. Fredenburgh

Blood (2017) 129 (12): 1574–1575.

https://doi.org/10.1182/blood-2017-01-761593

Published: 2017

Journal Articles

Emerging anticoagulant strategies

James C. Fredenburgh, Peter L. Gross, Jeffrey I. Weitz

Blood (2017) 129 (2): 147–154.

https://doi.org/10.1182/blood-2016-09-692996

Published: 2017

Journal Articles

Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoprotein

Trang T. Vu, Ji Zhou, Beverly A. Leslie, Alan R. Stafford, James C. Fredenburgh, Ran Ni, Shengjun Qiao, Nima Vaezzadeh, Willi Jahnen-Dechent, Brett P. Monia, Peter L. Gross, Jeffrey I. Weitz

Blood (2015) 125 (17): 2712–2719.

https://doi.org/10.1182/blood-2014-11-611319

Published: 2015

Includes: Supplemental data

NARROW

The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial

Management of Edoxaban Therapy in Patients Undergoing Major Surgery: A Sub-Analysis of the Prospective, Observational, Multinational Emit-AF/VTE Study

Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial

Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis

COVID-19 coagulopathy, thrombosis, and bleeding

Novel antithrombotic strategies for treatment of venous thromboembolism

Association of Bleeding Severity with Mortality with Extended Thromboprophylaxis in the Medically Ill in the Mariner Trial

Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial

Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study

MAA868 locks factor XIa in a zymogen-like state

Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism

Medically Ill Patients with Moderate Renal Insufficiency Have More Thrombotic and Bleeding Events Than Those with Normal Renal Function: Insights from the Magellan and Mariner Trials of Extended Thrombprophylaxis

Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism

A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in the Prevention of Venous Thromboembolism after Elective Hip or Knee Replacement Surgery

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients Treated for Venous Thromboembolism

The Effect of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients with Nonvalvular Atrial Fibrillation

Platelet polyphosphate: the long and the short of it

Emerging anticoagulant strategies

Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoprotein

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only